Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma.

Hwang SR, Murga-Zamalloa C, Brown N, Basappa J, McDonnell SR, Mendoza-Reinoso V, Basrur V, Wilcox R, Elenitoba-Johnson K, Lim MS.

Lab Invest. 2017 Aug;97(8):962-970. doi: 10.1038/labinvest.2017.39. Epub 2017 Apr 17.

2.

NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.

Murga-Zamalloa CA, Mendoza-Reinoso V, Sahasrabuddhe AA, Rolland D, Hwang SR, McDonnell SR, Sciallis AP, Wilcox RA, Bashur V, Elenitoba-Johnson K, Lim MS.

Oncogene. 2017 Apr;36(15):2085-2094. doi: 10.1038/onc.2016.366. Epub 2016 Oct 3.

PMID:
27694894
3.

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8. doi: 10.1073/pnas.1420785112. Epub 2015 Mar 2.

4.

Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma.

McDonnell SR, Hwang SR, Rolland D, Murga-Zamalloa C, Basrur V, Conlon KP, Fermin D, Wolfe T, Raskind A, Ruan C, Jiang JK, Thomas CJ, Hogaboam CM, Burant CF, Elenitoba-Johnson KS, Lim MS.

Blood. 2013 Aug 8;122(6):958-68. doi: 10.1182/blood-2013-01-482026. Epub 2013 Jun 27.

5.

NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis.

McDonnell SR, Hwang SR, Basrur V, Conlon KP, Fermin D, Wey E, Murga-Zamalloa C, Zeng Z, Zu Y, Elenitoba-Johnson KS, Lim MS.

Oncogene. 2012 Aug 9;31(32):3733-40. doi: 10.1038/onc.2011.542. Epub 2011 Dec 19.

6.

Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.

Cho H, Black SC, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, Siegel K, Yu XH, McDonnell SR, Chen P, Yie J, Ogilvie KM, Fraser J, Briscoe CP.

Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1142-51. doi: 10.1152/ajpendo.90298.2008. Epub 2008 Aug 26.

7.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.

8.

LPS-induced biomarkers in mice: a potential model for identifying insulin sensitizers.

Briscoe CP, Looper D, Tran P, Herrera J, McDonnell SR, Bhat BG.

Biochem Biophys Res Commun. 2007 Sep 14;361(1):140-5. Epub 2007 Jul 10.

PMID:
17659259
9.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG.

Cancer Res. 2007 May 1;67(9):4408-17.

Supplemental Content

Loading ...
Support Center